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Research
The Organisation for Economic Co-operation
and Development (OECD) undertook the
revision of existing guidelines and develop-
ment of new guidelines for screening and test-
ing of potential endocrine disruptors in 1997
(OECD 1998). Validation of new guidelines is
managed by a Validation Management Group
(VMG). One VMG program is the rodent
Hershberger bioassay, which is intended to be
used as a screen for suspected androgen ago-
nists and antagonists, and to assist in com-
pound prioritization for further evaluation. In
the Hershberger program phase 1, standard-
ized protocols were developed and successfully
tested against the high-potency reference
androgen testosterone propionate (TP) and the
antiandrogen ﬂutamide (FLU). The protocols
were robust, reproducible, and transferable
across laboratories using these reference com-
pounds (Owens et al. 2006). Therefore, the
VMG proceeded with the design and execu-
tion of phase 2 to demonstrate the ability of
the protocol to identify weakly active andro-
genic and antiandrogenic substances and
5α-reductase inhibitors.
Phase 2 Design
The goals of the Hershberger phase 2 valida-
tion were as follows:
• To evaluate the reproducibility of the pro-
tocols for identifying weaker androgen ago-
nists and antagonists
• To evaluate the capability of the protocol to
detect a 5α-reductase inhibitor
• To continue to evaluate ﬁve target accessory
tissues and glands of the male reproductive
tract as mandatory protocol end points 
• To characterize possible sources of variabil-
ity among the participating laboratories.
Standardized protocol. The principle of
the Hershberger bioassay is that organs and
accessory tissues in the male reproductive tract
are under the control of androgens, which are
necessary to stimulate and maintain growth of
these tissues; the tissue growth response is rela-
tively rapid, allowing the assay to be con-
ducted in a matter of days; the tissue weights
are quantitative; and no specialized facilities or
equipment are necessary. The phase 2 andro-
genic and antiandrogenic protocols were
largely unchanged from phases 1A and 1B
(Owens et al. 2006). The primary modiﬁca-
tions were a) exclusion of dorsolateral prostate
weights; and b) speciﬁcation of castration on
or after postnatal day (PND) 42, because
some animals castrated before PND42 in
phase 1 did not undergo preputial separation,
compromising glans penis (GP) dissection.
The test protocols are based on weights of ﬁve
mandatory male reproductive tract tissues—
ventral prostate (VP), paired seminal vesicles
and coagulating glands (SVCG), the levator
ani and bulbocavernosus muscles (LABC), the
glans penis (GP), and the paired Cowper’s or
bulbourethral glands (COWS)—after 10 con-
secutive days of test substance administration
to castrated male rats. Optional protocol mea-
surements included liver weight, paired
adrenal weight, and paired kidney weight; lab-
oratories were permitted to perform other
measurements on a voluntary, information-
gathering basis. The mandatory, optional, and
investigational measurements performed by
each laboratory are identiﬁed in Table 1. The
full model protocol for phases 1A and 1B may
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OBJECTIVE: The Organisation for Economic Co-operation and Development (OECD) has
completed phase 2 of an international program to validate the rodent Hershberger bioassay.
DESIGN: The Hershberger bioassay is designed to identify suspected androgens and antiandrogens
based on changes in the weights of ﬁve androgen-responsive tissues (ventral prostate, paired seminal
vesicles and coagulating glands, the levator ani and bulbocavernosus muscles, the glans penis, and
paired Cowper’s or bulbourethral glands). Protocol sensitivity and reproducibility were tested using
two androgen agonists (17α-methyl testosterone and 17β-trenbolone), four antagonists [procymi-
done, vinclozolin, linuron, and 1,1-dichoro-2,2-bis-(p-chlorophenyl)ethylene (p,p´-DDE)], and a
5α-reductase inhibitor (ﬁnasteride). Sixteen laboratories from seven countries participated in phase 2.
RESULTS: In 40 of 41 studies, the laboratories successfully detected substance-related weight
changes in one or more tissues. The one exception was with the weakest antiandrogen, linuron, in
a laboratory with reduced sensitivity because of high coefﬁcients of variation in all tissue weights.
The protocols performed well under different experimental conditions (e.g., strain, diet, housing
protocol, bedding, vehicle). There was good agreement and reproducibility among laboratories
with regard to the lowest dose inducing signiﬁcant effects on tissue weights. 
CONCLUSIONS: The results show that the OECD Hershberger bioassay protocol is reproducible and
transferable across laboratories with androgen agonists, weak androgen antagonists, and a
5α-reductase inhibitor. The next validation phase will employ coded test substances, including
positive substances and negative substances having no androgenic or antiandrogenic activity.
KEY WORDS: androgen, antiandrogen, bulbocavernosus, Cowper’s glands, DDE, endocrine disrup-
tion, Finasteride, glans penis, Hershberger, levator ani, seminal vesicles, linuron, methyl testosterone,
procymidone, trenbolone, validation, ventral prostate, vinclozolin. Environ Health Perspect
115:671–678 (2007). doi:10.1289/ehp.9666 available via http://dx.doi.org/ [Online 17 January 2007]be found in Section I of the Supplementary
Material for Owens et al. (2006) (available
online at http://www.ehponline.org/docs/
2006/8751/suppl.pdf).
Participating laboratories. Sixteen labora-
tories from seven nations (Denmark, France,
Germany, Japan, the Republic of Korea, the
United Kingdom, and the United States) par-
ticipated in phase 2. All laboratories partici-
pated on a voluntary and self-supporting basis,
and all had participated in phase 1 (Owens
et al. 2006).
Chemicals and selected doses. An impor-
tant criterion for a validation study is the
demonstration of the ability to correctly iden-
tify the outcomes in the assays to be replaced
or the outcomes from the apical assays
(OECD 2005). Therefore, compounds were
selected that produced androgenic or anti-
androgenic effects in reproductive and
developmental assays. These studies also pro-
vided no observed effect level (NOEL) and
lowest observed effect level (LOEL) doses for
comparisons to the Hershberger bioassay data
(Bowman et al 2003; Clark et al. 1990; Gray
et al. 1994, 1999; Hellwig et al. 2000;
Imperato-McGinley et al. 1986; Kelce et al.
1995; McIntyre et al. 2000, 2002a, 2002b;
Monosson et al. 1999; Ostby et al. 1999;
Wilson et al. 2002; You et al. 1998).
Single chemical lots were purchased by the
European Chemical Industry Council and
Japan Chemical Industry Association and
transferred to a central chemical repository at
TNO, The Netherlands. The repository dis-
tributed chemicals to all laboratories with the
exception of trenbolone, which is a controlled
substance whose import and distribution are
regulated. Trenbolone was obtained by the
individual qualifying laboratories from a lot
reserved by the supplier for the validation pro-
gram. The reference agonist was testosterone
propionate [Chemical Abstracts Service registry
no. (CASRN) 57-85-2, 99.9% pure; Sigma-
Aldrich, St. Louis MO, USA), and the reference
antagonist was ﬂutamide (CASRN 13311-84-7,
> 99% pure; Sigma-Aldrich). The test sub-
stances were 17α-methyltestosterone [MT;
CASRN 58-18-4, 99.6% pure; Fluka, Buchs,
Switzerland), vinclozolin [VIN; 3-(3,5-
dichlorophenyl)-5-methyl-5-vinyl-1,3-oxazoli-
dine-2,4-dione; CASRN 50471-44-8, 99.2%
pure; BASF AG, Germany], procymidone
{PRO; 3-(3,5-dichlorophenyl)-1,5-dimethyl-3-
azabicyclo[3.1.0]hexane-2,4-dion; CASRN
32809-16-8, 99.9% pure; Riedel-de Haën,
Germany}, linuron [LIN; 3-(3,4-dichloro-
phenyl)-1-methoxy-1-methylurea); CASRN
330-55-2, 99% pure; Crescent Chemical Co.
Inc., Islandia, NY, USA), 17β-trenbolone
[TREN; 17β-hydroxyestra-4,9,11-trien-3-one;
CASRN 10161-33-8, 96.6% pure; Sigma-
Aldrich), p,p´-DDE [DDE; 1,1-dichoro-2,2-
bis-(p-chlorophenyl)ethylene); CASRN
72-55-9, 99.5% pure; Sigma-Aldrich), and
ﬁnasteride [FIN; CASRN 98319-26-7, 99.7%
pure; Apin Chemicals Ltd., Abingdon,
Oxfordshire, UK). 
The dose series for each substance was
specified in order to compare results and
assess test reproducibility among the laborato-
ries. To assess interlaboratory variability, each
substance was tested in at least three laborato-
ries. Because of budget concerns, seven labo-
ratories began testing approximately 1 year
before the others; these tests were designated
stage 1. In stage 1, the participating laborato-
ries used a stimulating TP dose of 0.2 mg/kg
body weight (bw)/day for the antagonist stud-
ies. In stage 2, the other laboratories used a
stimulating TP dose of 0.4 mg/kg bw/day. A
total of 41 separate studies were performed.
The doses tested are described in Table 2.
All substances were prepared in corn oil
based on repository instructions, with the
exception of laboratory 2, which used methyl
cellulose; the dose volumes to be administered
were calculated based on daily body weights in
order to maintain selected doses. All the doses
were administered for 10 consecutive days at
approximately 24-hr intervals. The animals
were sacriﬁced approximately 24 hr after the
ﬁnal dose was administered.
Animals and husbandry conditions.
Participating laboratories obtained animals
from their normal external or internal sources,
and recorded the strain and animal supply
sources. All studies were performed in accor-
dance with the OECD’s guidelines on animal
care (OECD 2000) and appropriate national
regulations. The specified husbandry condi-
tions were the same as in phase 1 (Owens
et al. 2006), and the actual parameters for
each laboratory are presented in Table 3.
Study management and quality control.
The laboratories were asked to perform the
studies under the OECD Good Laboratory
Practice guidelines (OECD 2002) and most,
but not all, did so. After the data were assem-
bled and an initial statistical analysis performed,
all laboratories were requested to audit their raw
Owens et al.
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Table 1. Measurements recorded by individual participating laboratories in phase 2 of the OECD Hershberger validation program.
Laboratory (substances dosed)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Measurements L,Tr,V F,M,P D,Tr,V D,L,M F,L,V F,L,M P,Tr,V D,M,P D,F,P D,V D,M,V D M,V D,V M M,D
Mandatory
V P YYYYY YYYYYYYYYYY
SVCG Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
LABC Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
G P YYYYY YYYYYYYYYYY
COWS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Optional
Liver Y Y Y Y Y Y Y Y Y N N N Y N Y Y
Adrenals Y Y Y Y Y Y Y Y Y N N N N N N Ya
Kidneys Y Y Y Y Y Y Y Y Y N N Y Y N N Y
Tissue ﬁxationb YYNYNYYYYNNNNNNY
Serum T and LH N Y N Yc NNNNNNNNYNNN
Abbreviations: D, p,p´-DDE; F, ﬁnasteride; L, linuron; LH, luteinizing hormone; M, methyl testosterone; N, did not perform optional end point; P, procymidone; T, testosterone; Tr, trenbolone;
V, vinclozolin; Y, performed mandatory or optional end point. Laboratory numbers were randomly assigned and do not reﬂect the laboratory names or countries of origin. 
aVentral prostate, seminal vesicles, Cowper’s glands, and adrenals were ﬁxed in laboratory 16. bVentral prostate was ﬁxed and reweighed after ﬁxation. cHormone analyses were done
for DDE only. 
Table 2. Selected doses for phase 2 substances.
Chemical Doses
p,p´-DDE Stage 1: 3, 10, 30, and 100 mg/kg bw/day; stage 2: 5, 16, 50, and 160 mg/kg bw/day
FIN 0.2, 1, 5, and 25 mg/kg bw/day
FLU 3 mg/kg bw/day
LIN 3, 10, 30, and 100 mg/kg bw/day
MT Stage 1: 0.05, 0.5, 5, and 50 mg/kg bw/day; stage 2: 0.5, 2, 10, and 40 mg/kg bw/day
PRO 3, 10, 30, and 100 mg/kg bw/day
TP Stage 1: 0.2 mg/kg bw/day; stage 2: 0.4 mg/kg bw/day 
TREN 0.3, 1.5, 8, and 40 mg/kg bw/day
VIN 3, 10, 30, and 100 mg/kg bw/daydata and to respond to speciﬁc queries on out-
liers and questionable values. A small number
of data corrections were made as a result.
Data reporting and statistical analyses.
Similar to phase 1, each participating labora-
tory received a standardized Excel spreadsheet
(Microsoft, Redmond, WA, USA) for record-
ing and transmitting data for analysis (Owens
et al. 2006). Data entered in the spreadsheet
included names and assigned duties of labora-
tory personnel; parameters such as rat strain,
diet, and bedding with suppliers and lots; dates
of castration and the initiation of treatment;
caging practices; the procedures used to ran-
domize animals into groups; individual animal
numbers, daily body weights, preputial separa-
tion observations times of administration,
administration volumes; clinical signs; and all
mandatory and optional end points measured.
The Lead Laboratory [U.S. Environmental
Protection Agency (EPA); laboratory of L.E.G.]
performed its series of statistical calculations
using PROC MEANS and PROC GLM in
SAS (version 6.08; SAS Institute, Cary, NC,
USA) based on an analysis of covariance
(ANCOVA) F-test, followed by a pairwise t-test
comparison between a group control and a test
substance group (Owens et al. 2006). The
OECD Secretariat conducted additional statis-
tical analyses for the mandatory end points
using S-Plus (Insightful Corp., Seattle, WA,
USA) based on Dunnett’s multiple comparison
procedure for multiple pairwise comparisons.
Both starting and terminal body weights were
used in an ANCOVA adjustment (Owens et al.
2006). Because group number inﬂuences the
Dunnett’s error term, positive TP controls, if
performed, were excluded in the agonist series,
and vehicle and positive FLU controls were
excluded from the antagonist and 5α-reductase
series. Outliers were observed in a few data sets
(deﬁned as Studentized Residuals > 4 or < –4),
but these outliers were included in all of the
statistical analyses results shown here. R2 values
for overall correlations and for different effects
(e.g., chemical and laboratory effects) were cal-
culated as reported previously (Owens et al.
2006) to assess the robustness of the dose
response for each tissue.
The primary difference between the two
statistical approaches is that pairwise t-test is
slightly more liberal in achieving statistical
signiﬁcance. That is, single pairwise compari-
sons may achieve statistical significance in
some marginal cases where Dunnett’s multi-
ple comparisons do not. The results of both
analyses are reported, side-by-side, for the
mandatory end points.
Using benchmark dose (BMD) methodol-
ogy, the results for each tissue were also com-
pared for both the individual laboratory and the
pooled data from all laboratories using the same
test substance and, where applicable, the same
stimulating TP dose. In these studies, a “hybrid”
model was ﬁt whereby the probability of being
abnormal was described using a Weibul distrib-
ution (Crump 1995). In this case, “abnormal”
was deﬁned by the 5th percentile of the control
distribution in the direction of adverse response
(lower percentile for a decreasing adverse
response, and upper percentile for increasing
adverse response). The BMD was deﬁned as the
dose that increases the risk or probability of
being “abnormal” by 5% over background.
The lower 95% conﬁdence limit of the BMD
(BMDL) was also calculated. The program
BENCH_C was used for all BMD calculations
(Crump and Van Landingham 1996).
Results
Phase 2, Stages 1 and 2: Androgen
Agonist Dose Responses
Two androgen agonists were employed as test
substances in phase 2. MT was tested in eight
laboratories using two overlapping dose series.
TREN was tested in three laboratories. All
laboratories completed their assigned studies
and provided the Excel spread sheets containing
all individual animal results and protocol
descriptions. For the agonist studies, the means,
SDs, and statistical results for the starting and
terminal body weights, all ﬁve mandatory tis-
sues, and measured optional organs from each
laboratory are available in the Supplemental
Material (http://www.ehponline.org/docs/
2007/9666/suppl.pdf).
Methyl testosterone. The detection of andro-
gen agonists was assessed in stage 1 by four labo-
ratories using doses of 0.05, 0.5, 5, and 50 mg
MT/kg bw/day and, in stage 2, by four labora-
tories using doses of 0.5, 2, 10, and 40 mg
MT/kg bw/day. All ﬁve male sex accessory tis-
sues responded to MT in a dose-responsive
manner, and all tissues achieved statistically sig-
niﬁcant weight increases in all laboratories. The
stage 1 MT studies were conducted approxi-
mately 1 year before the stage 2 MT studies.
The tissue responses across both stages were
reproducible based on the increases in tissue
weights relative to the vehicle control from the
eight individual laboratories, as illustrated by the
VP results (Figure 1). In laboratory 6, absolute
VP weights were less than half and absolute
COWS weights were only about one-sixth those
in other laboratories, suggesting differences in
the dissection and tissue handling techniques.
When the stage 1 data were pooled across
the participating laboratories, all ﬁve manda-
tory end points achieved statistical signiﬁcance
using the pairwise comparison approach from
5 mg MT/kg bw/day. The R2 analyses indi-
cated a strong overall chemical relationship
and a strong dose relationship, and suggested a
slight relationship for possible laboratory
effects for the GP. In those laboratories meas-
uring optional tissues, there were significant
OECD Hershberger bioassay: phase 2 dose–response studies
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Table 3. Laboratory parameters and conditions for phase 2 studies.
Age at Acclimation Age at Animals
Laboratory Rat strain castration (PND) time (days) necropsy (PND) Diet per cage
1 Wistar rats, CrlGlxBrlHan:Wl 44–46 7 61–63 Provimi Kliba SA (Provimi Kliba AG,  1
Kaiseraugst, Switzerland)
2 Sprague Dawley 43–45, 47 12, 10–11 64–67, 67–68 UAR, A04C-10 (Usine d'Alimentation  1
Rationnelle, Epinay sur Orge, France)
3 SPF-bred Wistar HsdCpb:WU 45–46 12–13 67–69 Provimi Kliba SA (Provimi Kliba AG) 3
4 Crl CD (SD) IGS BR Sprague Dawley 43–44, 44–46 12–14 69–70 A04 C SAFE  3
5 Brl:WIST Han@Mol outbred 42–45 14–15, 18 66–70, 70–73 Proprietarya 3
6 Crl:CD(SD)IGS BR 42 14–15 66–67 PMI 5002 (Purina Mills, St. Louis, MO, USA) 3
7 CD (SD) IGS BR 42–45 7 59–63 RM1 (Special Diet Services, Witham, UK) 3
8 Sprague Dawley 42 8 60 PMI 5057 (Purina Mills) 3
9 Alpk:APfSD 42–43 9–10 62–63 RM1 (Special Diet Services) 3
10 Brl Han: WIST Jcl (GALAS) 41–43 7 59–61 MF (Oriental Yeast Co., Tokyo, Japan) 3
11 Crj:CD IGS (SD)b 40–44 8 59–63 MF (Oriental Yeast Co.) 1
12 Brl Han: WIST Jcl (GALAS) 40–42 6 57–59 MF (Oriental Yeast Co.) 3
13 Crj:CD IGS (SD)b 41–44 11 63–66 MF (Oriental Yeast Co.) 1
14 Crj:CD IGS (SD)b 43–46 7 61–64 MF (Oriental Yeast Co.) 2
15 Crj:CD IGS (SD)b 41–43 7 59–61 MF (Oriental Yeast Co.) 3
16 Crj:CD IGS (SD) cb 42–44 7 60–62 MF (Oriental Yeast Co.) 2
Corn oil was used as vehicle except in laboratory 2, which used 0.5% methyl cellulose. 
aPuriﬁed (semisynthetic) diet, prepared at laboratory 5. bThe animals were from different facilities in the same country.increases in the liver weights and significant
decreases in the adrenal weights at 50 mg
MT/kg bw/day (data not shown).
When the stage 2 data were pooled across
the four participating laboratories, the VP,
LABC, and COWS achieved statistical signiﬁ-
cance using the pairwise comparison approach
from 2 mg MT/kg bw/day, and SVCG and
GP from 10 mg MT/kg bw/day. The R2 analy-
ses indicated a strong overall chemical relation-
ship and a strong dose relationship, and
suggested a slight relationship for possible labo-
ratory effects for the VP, LABC, and COWS.
There were no evident changes in body
weights with increasing MT doses. In the labo-
ratories measuring optional tissues, there were
signiﬁcant increases in the liver weights in lab-
oratories 2, 4, and 8 at 40 mg MT/kg bw/day,
signiﬁcant decreases in the adrenal weights in
laboratories 2, 4, and 6 at 40 mg/kg bw/day
MT, and signiﬁcant increases in paired kidney
weights in laboratories 4 and 8 from 10 mg
MT/kg bw/day and in laboratory 6 at 40 mg
MT/kg bw/day (data not shown).
Trenbolone. Three laboratories assessed the
detection of androgen agonists using doses of
0.3, 1.5, 8, and 40 mg TREN/kg bw/day.
TREN induced dose-related weight increases
in all ﬁve male sex accessory tissues, and all ﬁve
responses achieved statistical signiﬁcance with
the pairwise t-test approach. In laboratories 1
and 3, the VP and the SVCG were marginally
signiﬁcant with either, but not both, the start-
ing or terminal body weight adjustments at
40 mg/kg bw/day using the Dunnett’s multi-
ple comparisons approach. Within individual
laboratories, the coefﬁcients of variation (CVs)
were higher with the VP (29–51%), SVCG
(31–37%), and COWS (22–44%), again sug-
gesting that variations in dissection and tissue-
handling proficiency had an impact on the
achievement of statistical signiﬁcance.
When the data were pooled across laborato-
ries, all ﬁve mandatory end points achieved sta-
tistical signiﬁcance at 40 mg TREN/kg bw/day
using the pairwise comparison approach.
The absolute body weight gains during the
treatment period were reduced at the top two
doses of TREN, and were statistically signiﬁ-
cant at 40 mg/kg bw/day TREN in laborato-
ries 1 and 7 (p < 0.05) and when the data were
pooled (p < 0.01; data not shown). Liver,
paired adrenal, and paired kidney weights,
were not consistently or signiﬁcantly affected
by TREN administration (data not shown).
Phase 2: Antiandrogen Dose
Responses with Antagonists 
and a 5α-Reductase Inhibitor
Four androgen antagonists and a 5α-reductase
inhibitor were used as test substances. Eight
laboratories conducted studies with VIN and
DDE. The VIN doses were identical in all lab-
oratories, and there were two sets of overlap-
ping doses with DDE. PRO, LIN, and FIN
studies were conducted by four laboratories.
Laboratory 8, with a newly trained technician,
encountered several animal deaths due to gav-
age errors in an initial study with PRO, and
this laboratory voluntarily performed a second
study; both sets of data were included in the
overall analyses. For the antagonist studies, the
means, SDs, and statistical results for the start-
ing and terminal body weights, all ﬁve manda-
tory tissues, and optional organs from each
laboratory are available in the Supplemental
Material (http://www.ehponline.org/docs/
2007/9666/suppl.pdf).
Vinclozolin. Eight laboratories tested the
antagonistic effects of VIN using doses of 3,
10, 30, and 100 mg/kg bw/day. In stage 1,
four laboratories coadministered TP at
0.2 mg/kg bw/day, and in stage 2, four labora-
tories coadministered TP at 0.4 mg/kg bw/day.
The stage 1 studies were conducted approxi-
mately 1 year before the stage 2 studies. The
tissue responses were reproducible within and
across stages 1 and 2 and were consistent based
on the decreases in TP-stimulated tissue
weights relative to the TP-stimulated control
from the eight individual laboratories, as illus-
trated by the VP results (Figure 2). 
VIN induced dose-responsive, statistically
signiﬁcant decreases in all TP-stimulated tissues
with one exception. In laboratory 5, the GP
was dissected only where preputial separation
had occurred, reducing the high-dose group to
only two animals. The absolute GP tissue
weight decrease was similar to that seen in the
other laboratories, but statistical significance
was not achieved because of the small number
of samples. When the data were pooled across
the participating laboratories, all ﬁve mandatory
end points achieved statistical signiﬁcance using
the pairwise comparison approach from 10 mg
VIN/kg bw/day when using 0.2 mg TP/kg
bw/day, and although the GP response was
marginally insigniﬁcant, the other four manda-
tory end points achieved significance from
30 mg VIN/kg bw/day when using 0.4 mg
TP/kg bw/day. The absolute organ weights of
the liver and adrenals were statistically signiﬁ-
cantly increased by VIN administration from
30 mg/kg bw/day in all laboratories where these
measurements were made (data not shown).
p,p´-DDE. Nine laboratories assessed the
detection of the weak androgen antagonist
DDE. In stage 1, ﬁve laboratories used doses
of 3, 10, 30, and 100 mg DDE/kg bw/day
coadministered with 0.2 mg TP/kg bw/day;
in stage 2, four laboratories used doses of 5,
16, 50, and 160 mg DDE/kg bw/day co-
administered with 0.4 mg TP/kg bw/day.
The tissue responses within and across both
stages were reproducible, based on the
decreases in TP-stimulated tissue weights rela-
tive to the TP-stimulated control from the
eight individual laboratories, as illustrated by
the VP results (Figure 3).
In stage 1, DDE induced dose-responsive,
statistically signiﬁcant decreases in TP-stimu-
lated weight gains in all tissues in all laborato-
ries. When the data were pooled across
laboratories, four of the mandatory end points
achieved statistical significance from 30 mg
DDE/kg bw/day when using 0.2 mg TP/kg
bw/day, and the GP was signiﬁcant at 100 mg
DDE/kg bw/day. Where measured, the liver
weights were increased by DDE administration
Owens et al.
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Figure 1. Relative increases in VP mean weights
with MT administration in eight laboratories (Lab)
using two dose series (laboratories 2–8 used 0.5, 2,
10, and 40 mg/kg bw/day MT, and laboratories
11–16 used 0.05, 0.5, 5, and 50 mg/kg bw/day MT). 
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Figure 2. Relative decreases in VP mean weights
using VIN against TP controls in eight laboratories
(Lab). Laboratories 1–7 used a stimulating dose of
0.4 mg/kg bw/day TP, and laboratories 10–14 used
a stimulating dose of 0.2 mg/kg bw/day TP.
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Figure 3. Relative decreases in VP mean weights
using p,p´-DDE against TP controls in nine labora-
tories (Lab). Laboratories 3–9 used a stimulating
dose of 0.4 mg/kg bw/day TP with doses of 5, 16, 50,
and 160 mg/kg bw/day DDE, and laboratories 10–16
used a stimulating dose of 0.2 mg/kg bw/day TP
with doses of 3, 10, 30, and 100 mg/kg bw/day DDE.(data not shown), and there was a consistent,
small, but not statistically significant decre-
ment in terminal body weights at the high dose
of 100 mg DDE/kg bw/day.
In stage 2, DDE induced dose-responsive,
statistically signiﬁcant decreases in TP-stimu-
lated weight gains in all tissues in all laborato-
ries, with two exceptions. In laboratory 4, the
SVCG and the GP did not decrease in a simi-
lar absolute magnitude compared with the
other laboratories. When the data were pooled
across the participating laboratories, four tis-
sues had significant decreases with both the
pairwise and multiple comparison statistical
approaches from 50 mg DDE/kg bw/day
when using 0.4 mg TP/kg bw/day. The GP
weights were signiﬁcantly decreased using the
pairwise approach, but statistical signiﬁcance
was observed in the pooled data only at
160 mg DDE/kg bw/day with Dunnett’s
approach. The absolute body weights were
decreased at the high dose of 100 mg/kg (data
not shown), and the decrease was statistically
significant in laboratories 4, 8, and 9. Liver
weight increases were statistically signiﬁcant in
all laboratories from 16 mg DDE/kg bw/day,
and the absolute increase ranged from 47 to
60% at the high dose (data not shown).
Procymidone. Four laboratories assessed
the detection of this androgen antagonist
using doses of 3, 10, 30, and 100 mg PRO/kg
bw/day coadministered with 0.4 mg TP/kg
bw/day.
PRO induced dose-responsive, statistically
signiﬁcant decreases in TP-stimulated weight
gains in all ﬁve tissues in laboratories 8 and 9.
In laboratories 2 and 7, the absolute GP
weights decreased but did not achieve signiﬁ-
cance. When the data were pooled across labo-
ratories, all five mandatory end points
achieved statistical signiﬁcance using the pair-
wise comparison approach from 30 mg
PRO/kg bw/day, and the GP achieved signiﬁ-
cance using the Dunnett’s approach, if starting
body weights were used in the ANCOVA.
Body weight gains during PRO treatment
were reduced by 10–20 g at the high dose, and
the reductions were signiﬁcant in laboratory 8
at 100 mg PRO/kg bw/day. Liver weights
were signiﬁcantly increased in all laboratories,
and the paired adrenal weights were signifi-
cantly increased in laboratories 2, 7, and 8
(data not shown).
Linuron. Four laboratories assessed the
detection of this weak androgen antagonist
using doses of 3, 10, 30, and 100 mg LIN/kg
bw/day coadministered with 0.4 mg TP/kg
bw/day.
LIN induced positive responses at the high
dose in three of four laboratories. In labora-
tory 6, absolute weights of GP and COWS
were largely unchanged, and the absolute
decreases in VP, SVCG, and LABC weights
were modest compared with values from the
other laboratories. The SVCG achieved mar-
ginal signiﬁcance using the t-test approach but
was not significant with the Dunnett’s
approach. Many tissue CVs in this laboratory
were very high, particularly in the control
group (VP 40.8%, SVCG 36.9%, COWS
64.9%), suggesting tissue dissection was a
major factor in failing to detect LIN. When
the data were pooled across the laboratories,
four of the mandatory end points achieved sta-
tistical significance using both the pairwise
comparison and Dunnett’s multiple compari-
son approaches at 100 mg LIN/kg bw/day.
However, the GP did not achieve signiﬁcance
with the Dunnett’s method. Body weights
were signiﬁcantly decreased in laboratories 1
and 4 by LIN treatment, and absolute values
decreased by 15–20 g in laboratories 5 and 6.
No optional organ weight changes were attrib-
utable to LIN because weights decreased in
relative proportion to body weight.
Finasteride. Four laboratories assessed the
detection of potent 5α-reductase inhibitors
using doses of 0.2, 5, 30, and 25 mg FIN/kg
bw/day coadministered with 0.4 mg TP/kg
bw/day.
FIN was easily detected in this protocol.
A NOEL was not observed in one or more
tissues at the lowest dose of 0.2 mg FIN/kg
bw/day in three of the four laboratories. The
absolute weights of all five sex accessory tis-
sues decreased in a dose-responsive manner.
The VP, SVCG, and COWS decreases were
statistically significant in all laboratories at
25 mg FIN/kg bw/day. However, the LABC
weight decrease was not consistently signifi-
cant in laboratory 6, and the response of GP
did not achieve signiﬁcance in laboratories 2
and 6. When the data were pooled, all tissues
achieved significance from 0.2 mg FIN/kg
bw/day using pairwise comparisons, and all
tissues, with the exception of COWS, were
signiﬁcant with the Dunnett’s approach from
this same dose. Finasteride had no discernable
impact on body weights, body weight gains,
or optional organ weights (data not shown).
Tissue LOELs with Agonist and
Antagonists
The LOELs for each tissue were compared
within each laboratory and across laboratories
to assess the reproducibility and sensitivities of
the ﬁve target tissues and the stimulating doses
of 0.2 and 0.4 mg TP/kg bw/day with weak
antiandrogens. The LOELs for all tissues and
individual studies are available in the
Supplemental Material (http://www.ehponline
.org/docs/2007/9666/suppl.pdf). The large
majority of LOELs for all five tissues fall
between 0.5 and 1 order of magnitude for
each substance across the participating labora-
tories. This demonstrates a high degree of
reproducibility of the dose responses in the
Hershberger bioassay across laboratories. As
would be expected for a lower stimulating
dose and constant antiandrogen dose, the
LOELs were slightly lower for both VIN and
DDE when 0.2 mg TP/kg bw/day was used
compared with when 0.4 mg TP/kg bw/day
was used.
All ﬁve sex accessory tissues achieved sta-
tistically signiﬁcant LOELs using the t-test in
33 of a total of 41 studies. In one study (labo-
ratory 5 with VIN), the GP was not dissected
in four animals because of a lack of preputial
separation. In the remaining seven studies,
the GP consistently failed to achieve statistical
significance, and all of these incidents were
with antiandrogens. The only instance in
which more than one tissue did not achieve
statistical significance was the test with LIN
by laboratory 6. A review of tissue sensitivity
in Table 4 suggests overall equivalent sensitiv-
ity among the other four tissues (VP, SVCG,
LABC, and COWS) with both androgens
and antiandrogens.
Benchmark Dose Analyses
BMDs were calculated for each mandatory tis-
sue within each laboratory and across laborato-
ries to compare the reproducibility and
sensitivities of the ﬁve target tissues and also to
compare the stimulating doses of 0.2 and
0.4 mg TP/g bw/day with weak antiandrogens.
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Table 4. Summary of the LOEL dose performance (by the number of laboratories) of the ﬁve mandatory tis-
sues in each phase 2 study. 
Test substance VP SVCG LABC GP COWS
Androgen agonists
MT 8 8 8 8 8
TREN 3 3 3 3 3
Androgen antagonists
PRO 5 5 5 4 5
VIN 8 8 8 7 8
LIN 3 4 4 1 3
DDE 9 9 9 9 9
5α-Reductase inhibitor
FIN 4 4 4 3 4
Times a single tissue was the most sensitive end point 4 3 0 0 1
Times the tissue was equally sensitive with at least one other tissue 30 27 29 13 23
Times tissue was not statistically signiﬁcant by either approach 1a 01 a 7a 1a
aOne common instance was laboratory 6 with LIN.The BMDs for all tissues in the individual lab-
oratories are reported in the Supplemental
Material (http://www.ehponline.org/docs/
2007/9666/suppl.pdf). Although most BMDs
for a tissue were in good agreement across lab-
oratories, there were occasional exceptions.
These exceptions were attributed to one of
several causes: a) there were only four doses
available and the group size was only six
animals, which introduced variation and
uncertainty; b) in several cases, the LOEL
occurred only at the highest dose and the
absolute response was small, leaving only this
one responsive dose in the BMD calculation,
also introducing variation and uncertainty;
and c) the TP-stimulated baseline was variable
at the lower doses (i.e., the baseline means
were sometimes as much as 20% higher or
lower than the control, thereby introducing
variability into the BMD modeling). As noted
with the LOELs, the BMDs for GP were simi-
lar to the other tissues in the case of andro-
gens, but were consistently higher in the case
of antiandrogens. The BMDs, as would be
expected for a lower stimulating dose and con-
stant antiandrogen dose, were slightly lower
for 0.2 mg TP/kg bw/day than for 0.4 mg
Owens et al.
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Table 6. Comparisons of LOELs from Hershberger target tissues in validation phase 2 with those from developmental and reproductive studies using the same test
substances.
Chemical Hershberger tissue LOELs Developmental and/or reproductive bioassay LOELs
TREN VP: 8–40 mg/kg bw/day Wilson et al. (2002) (subcutaneous administration)
SVCG: 40 mg/kg bw/day ↑ Female anogenital distance ≥ 0.5 mg/kg bw/day
LABC: 8–40 mg/kg bw/day ↓ Female areolas retention ≥ 2 mg/kg bw/day
GP: 8–40 mg/kg bw/day ↓ Female nipple retention ≥ 0.5 mg/kg bw/day
COWS: 40 mg/kg bw/day No frank malformations observed in females
VIN VP: 10–100 mg/kg bw/day Gray et al. (1994); Monosson et al. (1999)
SVCG: 10–30 mg/kg bw/day Anogenital distance ↓≥3.125 mg/kg bw/daya
LABC: 10–100 mg/kg bw/day Nipple retention ↑ PND14 males ≥ 50 mg/kg bw/day
GP: 10–100 mg/kg bw/day Nipple retention ↑ in pubertal males ≥ 50 mg/kg bw/day
COWS: 10–100 mg/kg bw/day Malformations (hypospadias) ↑≥50 mg/kg bw/day
↓ Adult VP weight at ≥ 50 mg/kg bw/day
↓ Sperm count at 100 mg/kg bw/day
DDE VP: 30–160 mg/kg bw/day Gray et al. (1994); Kelce et al. (1995); You et al. (1998)
SVCG: 30–160 mg/kg bw/day Anogenital distance ↓ in LE but not SD rats 100 mg/kg bw/day
LABC: 30–100 mg/kg bw/day Nipple retention ↑ PND13 males 10 mg/kg bw/day SD rats; 100 mg/kg bw/day LE rats
GP: 100–160 mg/kg bw/day Malformations (hypospadias) low ↑ at 100 mg/kg bw/day in one study but not observed in second study
COWS: 30–100 mg/kg bw/day ↓ Adult VP wts 200 mg/kg bw/day
PRO VP: 10–30 mg/kg bw/day Gray et al. (1994); Ostby et al. (1999)
SVCG: 10–30 mg/kg bw/day Anogenital distance ↓≥25 mg/kg bw/day
LABC: 3–100 mg/kg bw/day Retained nipples ↑≥50 mg/kg bw/day
GP: ND–10 mg/kg bw/day Malformations (hypospadias) ↑≥50 mg/kg bw/day
COWS: 3–100 mg/kg bw/day Decreased adult sex accessory tissue weights ≥ 100 mg/kg bw/day
Histopath lesions ↑ in adult sex accessory tissue ≥ 50 mg/kg bw/day
LIN VP: ND–30 mg/kg bw/day Gray et al. (1994); McIntyre et al. (2000, 2002a, 2002b)
SVCG: 30–100 mg/kg bw/day Anogenital distance not statistically signiﬁcant up to 50 mg/kg bw/day
LABC: ND–30 mg/kg bw/day Nipple retention ↑ PND13 males 50 mg/kg bw/day
GP: ND–100 mg/kg bw/day Nipple retention ↑ in pubertal males ≥ 50 mg/kg bw/day
COWS: ND–100 mg/kg bw/day Malformations (epididymis) ↑≥25 mg/kg bw/day
↓ Adult dorsolateral prostate weights 50 mg/kg bw/day
Histological abnormalities ↑ in male repro tract ≥ 25 mg/kg bw/day
FINb VP: 0.2–1 mg/kg bw/day Bowman et al. (2003); Clark et al. (1990); Imperato-McGinley et al. (1986, 1992)
SVCG: 0.2–1 mg/kg bw/day Anogenital distance ↓ PND1 ≥ 0.01 mg/kg bw/day
LABC: 0.2–5 mg/kg bw/day Nipple retention ↑ PND13 males ≥ 0.01 mg/kg bw/day
GP: ND–0.2 mg/kg bw/day Nipple retention ↑ in adult males ≥ 0.1 mg/kg bw/day
COWS: 0.2–5 mg/kg bw/day Malformations ↑ in multiple tissues ≥ 10 mg/kg bw/day
↓ Adult LABC weights ≥ 1 mg/kg bw/day
↓ Adult VP and COWS weights ≥ 10 mg/kg bw/day
aHellwig et al. (2000) did not observe anogenital changes at these concentrations in a multigenerational study. bThe lowest dose used in the validation study was 0.2 mg/kg bw/day; the
data of Bowman et al. (2003) were not available when the doses for this study were selected.
Table 5. BMDs (mg/kg bw/day) and CVs for all laboratories combined.
BMD (BMDL); mean CV
Chemical VP SVCG LABC GP COWS Liver
Androgens
MT, stage 1 0.51 (0.37); 22.0 0.94 (0.66); 19.5 0.95 (0.67); 12.1 9.1 (2.9); 7.2 0.53 (0.39); 21.7 NE
MT, stage 2 3.0 (1.3); 40.5 4.8 (2.6); 31.3 2.0 (0.69); 16.4 1.8 (0.89); 18.1 1.7 (0.65); 33.4 NE
TREN  8.8 (2.2); 34.2 13.8 (4.1); 33.2 5.1 (1.5); 17.7 7.7 (3.2); 10.3 15.9 (5.3); 30.5 NE 
Antiandrogens
PRO (0.4 mg TP/kg bw/day) 1.5 (1.1); 22.3 2.2 (1.4); 19.8 5.9 (3.8); 15.2 17.8 (10.0); 10.9 3.7 (2.5); 22.5 NE
VIN (0.2 mg TP/kg bw/day) 2.3 (1.2); 19.5 2.7 (1.2); 18.8 4.6 (1.9); 11.2 7.6 (2.7); 7.4 3.6 (1.8); 19.4 NE
VIN (0.4 mg TP/kg bw/day) 9.2 (3.1); 24.6 12.2 (5.1); 20.0 8.7 (4.0); 12.6 36.0 (9.8); 10.7 35.1 (11.5); 22.9 NE
LIN (0.4 mg TP/kg bw/day) 38.3 (19.1); 25.6 22.0 (8.2); 21.7 31.3 (10.6); 12.2 100 (48.1); 12.0 44.8 (15.6); 25.3 NE
p;p´-DDE (0.2 mg TP/kg bw/day) 16.1 (6.2); 21.9 12.5 (5.4); 18.5 13.0 (5.1); 11.0 95.6 (71.5); 8.5 26.5 (11.3); 19.2 2.2 (0.71); 7.1
p;p´-DDE (0.4 mg TP/kg bw/day) 23.6 (10.1); 23.7 22.1 (10.8); 22.0 17.9 (5.7); 11.9 54.2 (21.7); 10.5 11.8 (5.8); 18.4 3.9 (2.7); 8.8
5α-Reductase inhibitor
FIN (0.4 mg TP/kg bw/day) 0.87 (0.57); 28.7 1.4 (0.85); 25.8 8.8 (4.0); 11.9 20.6 (6.8); 9.8 0.77 (0.51); 29.2 NE
NE, no dose–response effect, so no BMD could be calculated. TP/kg bw/day for both VIN and DDE. There
were three cases, all in laboratory 6, where the
BMD calculation did not indicate a dose–
response relationship: the GP and COWS
using LIN, and the GP using FIN.
The BMD calculations and tissue CVs for
pooled data have been summarized for all ﬁve
mandatory tissues and all test substances
(Table 5). For agonists, no consistent differ-
ences in sensitivity among tissues were
observed. For antagonists, the GP was consis-
tently, albeit modestly, less sensitive than the
other tissues. In addition, with DDE, the BMD
for an increase in liver weight was less than the
BMDs for any of the mandatory tissues.
Discussion
There is a regulatory need for the Hershberger
bioassay to identify and assist in the prioritiza-
tion of test substances that may have andro-
genic or antiandrogenic mechanisms of action.
Antiandrogens are a particular concern because
of their effects on in utero male reproductive
tract development. The growth responses of
the Hershberger target tissues are relevant
because this growth depends upon the andro-
gen receptor (AR) and 5α-reductase activity.
Further, adsorption, distribution, metabolism,
and excretion interactions are sufﬁciently simi-
lar between the castrated male, the intact male,
and the in utero exposures, to the Hershberger
bioassay’s relevance.
This phase 2 validation was intended to
test the sensitivity and reproducibility of the
Hershberger protocol with androgens and anti-
androgens with weaker potencies than the
phase 1 reference substances, and also to test
the ability of the protocol to reproducibly iden-
tify 5α-reductase inhibitors. The data support
the conclusion that the OECD Hershberger
assay protocol is sufﬁciently sensitive, robust,
and reproducible to detect androgenic and
antiandrogenic activities of chemicals, and can
also detect 5α-reductase inhibitors. All labora-
tories were successful in detecting weight
increases in multiple target tissues after treat-
ment with MT and TREN, as well as weight
decreases of multiple target TP-stimulated tis-
sue weights with VIN, DDE, and FIN. Three
of four laboratories testing LIN were success-
ful; however, laboratory 6—with very high tis-
sue CVs in both control and test substance
groups—achieved marginal statistical signiﬁ-
cance in only one tissue (SVCG). Based on
the CVs from this laboratory, this failure can
be attributed to variability in tissue dissection
and handling. As with the phase 1 validation
study (Owens et al. 2006), some laboratories
consistently had lower CVs, further indicating
proﬁciency differences in dissection.
Despite differences in absolute body
weights, the percentage responses of the tis-
sues relative to the controls was very similar as
shown in Figures 1, 2, and 3. Six animals per
dose group were sufficient to detect the
androgenic and antiandrogenic activities of
these compounds. The ability of the OECD
Hershberger bioassay protocol to detect these
androgenic changes was not affected by differ-
ences in rat strain, diet, caging, routine labo-
ratory procedures, or modest differences in
the ages at which the animals were castrated.
As with the phase 1 study, no added value
could be attributed to several other measure-
ments, for example, weights of fixed tissue
and serum hormone (T or LH) analyses.
Liver, kidney, and adrenal weights did pro-
vide supporting information on some chemi-
cals and treatment conditions (e.g., liver
weight increases with DDE).
The utility and sensitivity of the five
mandatory sex accessory tissues were also eval-
uated using calculated LOELs and BMDs.
There was good agreement among the individ-
ual tissues across laboratories with androgens
when either the LOELs or BMDs were used.
With antiandrogens, the GP was slightly less
responsive than the other four mandatory tis-
sues. The results were also in good agreement
for each antiandrogenic test substance across
laboratories based on LOELs, and also for
BMDs, taking into account the effect of varia-
tion in the baseline TP-stimulated tissue
weights on the BMD modeling.
For the optional tissues, the liver response
with DDE is of interest. In the parallel valida-
tion of enhancements to the 28-day repeat
dose study (Test Guideline 407), liver
enlargement occurred at similar doses and
paralleled increases in thyroid weight and
histopathology, supporting an increased
hepatic metabolism and excretion of thyroid
hormones (OECD 2006). This raises the pos-
sibility that p,p´-DDE operates through mul-
tiple modes of action, and illustrates the need
for a weight-of-evidence approach that takes
all available data into account.
The results of the Hershberger bioassay
with these test substances have been compared
with results of androgen and antiandrogen
study outcomes from developmental and
reproductive assays (Table 6). A prerequisite
for validation is an assessment of the predictive
power of assays that will replace another assay
or that operate at lower tiers (OECD 2005).
This comparison supports the conclusion that
the Hershberger assay is of value as a screening
assay to identify and prioritize substances for
possible adverse effects elicited through andro-
genic or antiandrogenic modes of action, and
supports the hypothesis that the predictions
from the lower-tier Hershberger assay are valid
for higher tier tests.
Conclusion
The results show that the OECD Hershberger
assay protocols are robust, reproducible, and
transferable across laboratories when using
a range of androgens and antiandrogens of
different potencies. The next phases of
the OECD validation program will test the
protocol’s reproducibility over time using
blinded doses of positive test substances
and chemicals having no androgenic or
antiandrogenic activity.
REFERENCES
Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PMD.
2003. Effects of in utero exposure to ﬁnasteride on andro-
gen-dependent reproductive development in the male rat.
Toxicol Sci 74:393–406.
Clark RL, Antonello JM, Grossman SJ, Wise LD, Anderson C,
Bagdon WJ, et al. 1990. External genitalia abnormalities in
male rats exposed in utero to ﬁnasteride, a 5α-reductase
inhibitor. Teratology 42:91–100.
Crump KS. 1995. Calculation of benchmark doses for continuous
data. Risk Anal 15:79–89.
Crump KS, Van Landingham C. 1996. BENCH_C: A Fortran
Program to Calculate Benchmark Doses from Continuous
Data. Ruston, LA:ICF Consulting. 
Gray LE Jr, Ostby JS, Kelce WR. 1994. Developmental effects of
an environmental antiandrogen: the fungicide vinclozolin
alters sex differentiation of the male rat. Toxicol Appl
Pharmacol 129:46–52.
Gray LE Jr, Wolf C, Lambright C, Mann P, Price M, Cooper RL,
et al. 1999. Administration of potentially antiandrogenic
pesticides (procymidone, linuron, iprodione, chlozolinate,
p,p´-DDE, and ketoconazole) and toxic substances
(dibutyl- and diethylhexyl phthalate, PCB 169, and ethane
dimethane sulphonate) during sexual differentiation pro-
duces diverse profiles of reproductive malformations in
the male rat. Toxicol Ind Health 15:94–118.
Hellwig J, van Ravenzwaay B, Mayer M, Gembardt C. 2000.
Pre- and postnatal oral toxicity of vinclozolin in Wistar and
Long-Evans rats. Regul Toxicol Pharmacol 32:42–50.
Imperato-McGinley J, Binieda Z, Gedney J, Vaughan ED Jr.
1986. Nipple differentiation in fetal male rats treated with
an inhibitor of the enzyme 5α-reductase: definition of
selective role for dihydrotestosterone. Endocrinology
118:132–137.
Imperato-McGinley J, Sanchez RS, Spencer JR, Yee B, Vaughan
ED. 1992. Comparison of the effects of 5α-reductase
inhibitor finasteride and the antiandrogen flutamide on
prostate and genital differentiation: dose-response studies.
Endocrinology 131:1149–1156.
Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA,
Wilson EM. 1995. Persistent DDT metabolite p,p´-DDE is a
potent androgen receptor antagonist. Nature 375:581–585.
McIntyre BS, Barlow NJ, Foster PMD. 2002a. Male rats exposed
to linuron in utero exhibit permanent changes in anogenital
distance, nipple retention, and epididymal malformations
that result in subsequent testicular atrophy. Toxicol Sci
65:62–70.
McIntyre BS, Barlow NJ, Sar M, Wallace DG, Foster PM.
2002b. Effects of in utero linuron exposure on rat Wolfﬁan
duct development. Reprod Toxicol 16:131–139.
McIntyre BS, Barlow NJ, Wallace DG, Maness SC, Gaido KW,
Foster PMD. 2000. Effects of in utero exposure to linuron
on androgen-dependent reproductive development in the
male Crl:CD(SD)BR rat. Toxicol Appl Pharmacol 167:87–99.
Monosson E, Kelce WR, Lambright CR., Ostby J, Gray LE Jr.
1999. Peripubertal exposure to the antiandrogenic fungi-
cide, vinclozolin, delays puberty, inhibits the development
of androgen-dependent tissues, and alters androgen recep-
tor function in the male rat. Toxicol Ind Health 15:65–79.
OECD. 1998. Report of the First Meeting of the OECD Endocrine
Disrupter Testing and Assessment (EDTA) Working Group,
10th–11th March 1998, ENV/MC/CHEM/RA(98)5. Paris:
Organization for Economic Cooperation and Development.
OECD. 2000. Guidance Document on the Recognition,
Assessment, and Use of Clinical Signs as Humane
Endpoints for Experimental Animals Used in Safety
Evaluations. OECD Environmental Health and Safety
Publications. Series on Testing and Assessment, No. 19.
ENV/JM/MONO (2000)7. Paris:Organization for Economic
Cooperation and Development. Available: http://www.
olis.oecd.org/olis/2000doc.nsf/LinkTo/env-jm-mono(2000)7
[accessed 21 March 2007]. 
OECD Hershberger bioassay: phase 2 dose–response studies
Environmental Health Perspectives • VOLUME 115 | NUMBER 5 | May 2007 677Owens et al.
678 VOLUME 115 | NUMBER 5 | May 2007 • Environmental Health Perspectives
OECD. 2002. OECD Series on Principles of Good Laboratory
Practice and Compliance Monitoring. Available: http://
www.oecd.org/document/63/0,2340,en_2649_34381_
2346175_1_1_1_1,00.html [accessed 21 March 2007]. 
OECD. 2005. Guidance Document on the Validation and
International Acceptance of New or Updated Test Methods
for Hazard Assessment. OECD Series on Testing and
Assessment, Number 34, Paris:Organisation for Economic
Co-operation and Development. Available: http://appli1.
oecd.org/olis/2005doc.nsf/linkto/env-jm-mono(2005)14
[accessed 21March 2007]. 
OECD. 2006. The Validation of the Enhanced Test Guideline 407
Repeat Dose 28-Day Oral Toxicity Study in Laboratory
Rats. Series on Testing and Assessment Number 59.
Paris:Organisation for Economic Co-operation and
Development. Available: http://www.oecd.org/dataoecd/
56/24/37376909.pdf [accessed 21 March 2007]. 
Ostby J, Kelce WR, Lambright C, Wolf C, Mann P, Gray LE Jr.
1999. The fungicide procymidone alters sexual differentia-
tion in the male rat by acting as an androgen-receptor
antagonist in vivo and in vitro. Toxicol Ind Health 15:80–93.
Owens W, Zeiger E, Walker M, Ashby J, Onyon L, Gray LE Jr.
2006. The OECD program to validate the rat Hershberger
bioassay to screen compounds for in vivo androgen and
antiandrogen responses. Phase 1: use of a potent agonist
and a potent antagonist to test the standardized protocol.
Environ Health Perspect 114:1259–1265.
Wilson VS, Lambright C, Ostby J, Gray LE Jr. 2002. In vitro and
in vivo effects of 17β-trenbolone: a feedlot efﬂuent conta-
minant. Toxicol Sci 70:202–211.
You L, Casanova M, Archibeque-Engle S, Sar M, Fan LQ,
Heck HA. 1998. Impaired male sexual development in perina-
tal Sprague-Dawley and Long-Evans hooded rats exposed in
utero and lactationally to p,p´-DDE. Toxicol Sci 45:162–173.